500 related articles for article (PubMed ID: 14668111)
1. Physiologically based pharmacokinetic modeling of arsenic in the mouse.
Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ
J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tissue dosimetry in the mouse following chronic exposure to arsenic compounds.
Gentry PR; Covington TR; Lawrence G; McDonald T; Snow ET; Germolec D; Moser G; Yager JW; Clewell HJ
J Toxicol Environ Health A; 2005 Mar; 68(5):329-51. PubMed ID: 15799626
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.
Kenyon EM; Hughes MF; Adair BM; Highfill JH; Crecelius EA; Clewell HJ; Yager JW
Toxicol Appl Pharmacol; 2008 Nov; 232(3):448-55. PubMed ID: 18706920
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate.
Kenyon EM; Del Razo LM; Hughes MF
Toxicol Sci; 2005 May; 85(1):468-75. PubMed ID: 15703264
[TBL] [Abstract][Full Text] [Related]
5. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice.
Xie Y; Trouba KJ; Liu J; Waalkes MP; Germolec DR
Environ Health Perspect; 2004 Aug; 112(12):1255-63. PubMed ID: 15345372
[TBL] [Abstract][Full Text] [Related]
6. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans.
Mann S; Droz PO; Vahter M
Toxicol Appl Pharmacol; 1996 Oct; 140(2):471-86. PubMed ID: 8887465
[TBL] [Abstract][Full Text] [Related]
7. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
[TBL] [Abstract][Full Text] [Related]
8. Inorganic and methylated arsenic compounds induce cell death in murine macrophages via different mechanisms.
Sakurai T; Kaise T; Matsubara C
Chem Res Toxicol; 1998 Apr; 11(4):273-83. PubMed ID: 9548797
[TBL] [Abstract][Full Text] [Related]
9. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
10. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.
Cohen SM; Arnold LL; Eldan M; Lewis AS; Beck BD
Crit Rev Toxicol; 2006 Feb; 36(2):99-133. PubMed ID: 16736939
[TBL] [Abstract][Full Text] [Related]
11. Developmental and reproductive toxicity of inorganic arsenic: animal studies and human concerns.
Golub MS; Macintosh MS; Baumrind N
J Toxicol Environ Health B Crit Rev; 1998; 1(3):199-241. PubMed ID: 9644328
[TBL] [Abstract][Full Text] [Related]
12. A Weibull-PBPK model for assessing risk of arsenic-induced skin lesions in children.
Liao CM; Lin TL; Chen SC
Sci Total Environ; 2008 Mar; 392(2-3):203-17. PubMed ID: 18207220
[TBL] [Abstract][Full Text] [Related]
13. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water.
Chen B; Arnold LL; Cohen SM; Thomas DJ; Le XC
Toxicol Sci; 2011 Dec; 124(2):320-6. PubMed ID: 21934131
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution and urinary excretion of dimethylated arsenic and its metabolites in dimethylarsinic acid- or arsenate-treated rats.
Adair BM; Moore T; Conklin SD; Creed JT; Wolf DC; Thomas DJ
Toxicol Appl Pharmacol; 2007 Jul; 222(2):235-42. PubMed ID: 17559899
[TBL] [Abstract][Full Text] [Related]
15. Arsenic-induced bladder cancer in an animal model.
Cohen SM; Ohnishi T; Arnold LL; Le XC
Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909
[TBL] [Abstract][Full Text] [Related]
16. Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells.
Naranmandura H; Ogra Y; Iwata K; Lee J; Suzuki KT; Weinfeld M; Le XC
Toxicol Appl Pharmacol; 2009 Jul; 238(2):133-40. PubMed ID: 19442679
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure.
Liao CM; Shen HH; Chen CL; Hsu LI; Lin TL; Chen SC; Chen CJ
J Hazard Mater; 2009 Jun; 165(1-3):652-63. PubMed ID: 19062162
[TBL] [Abstract][Full Text] [Related]
18. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan.
Tseng CH; Huang YK; Huang YL; Chung CJ; Yang MH; Chen CJ; Hsueh YM
Toxicol Appl Pharmacol; 2005 Aug; 206(3):299-308. PubMed ID: 16039941
[TBL] [Abstract][Full Text] [Related]
19. Arsenic speciation transported through the placenta from mother mice to their newborn pups.
Jin Y; Xi S; Li X; Lu C; Li G; Xu Y; Qu C; Niu Y; Sun G
Environ Res; 2006 Jul; 101(3):349-55. PubMed ID: 16458287
[TBL] [Abstract][Full Text] [Related]
20. Assessing the cancer risk associated with arsenic-contaminated seafood.
Chen BC; Chou WC; Chen WY; Liao CM
J Hazard Mater; 2010 Sep; 181(1-3):161-9. PubMed ID: 20546995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
